Incruse Ellipta
Umeclidinium
Why Incruse Ellipta Costs $185.00 Per Claim
Incruse Ellipta (Umeclidinium) is used to treat asthma/copd. According to CMS Medicare Part D spending data, the program spent $345.0M on this drug, covering 224,000 beneficiaries across 1,860,000 claims.
A generic version of this drug is available, which means lower-cost alternatives exist. Patients should ask their pharmacist about generic Umeclidinium or talk to their doctor about therapeutic alternatives that may cost less.
Price Breakdown
Drug Details
Frequently Asked Questions
Incruse Ellipta (Umeclidinium) costs an average of $185.00 per claim based on Medicare Part D data. The estimated annual cost per patient is $1,540.00. Actual out-of-pocket costs depend on your insurance plan and pharmacy.
Yes, a generic version of Incruse Ellipta (Umeclidinium) is available. Generic medications typically cost 80-95% less than brand-name drugs. Ask your pharmacist about generic Umeclidinium.
Medicare Part D spent $345.0M on Incruse Ellipta, covering 224,000 beneficiaries across 1,860,000 claims. This makes it one of the tracked drugs in the Medicare spending dashboard.
Ask your pharmacist about generic Umeclidinium, which is typically much cheaper. You can also compare prices at different pharmacies, use prescription discount programs, or ask your doctor about therapeutic alternatives in the same drug class.
Related
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims.